Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial
Authors' conclusion
Treatment with ticagrelor dual antiplatelet therapy for one year after surgery reduced the risk of major adverse cardiovascular events at five years after coronary artery bypass grafting compared with aspirin monotherapy or ticagrelor monotherapy.
Study context
- Population
- Patients aged 18–80 years after elective CABG, 6 tertiary hospitals in China477 (95.4%) completed follow-up
- Participants
- 500 patients
- Comparison
- DAPT vs Ticagrelor monotherapy vs Aspirin monotherapy
- DAPTn = 168
- Ticagrelor monotherapyn = 166
- Aspirin monotherapyn = 166reference
- Primary endpoint
- MACE:
- All cause death
- MI
- Stroke
- Coronary revascularisation
- Follow-up
- 5 years
Methodological details5-year follow-up, multicentre, post hoc sensitivity analyses, After the first year, antiplatelet therapy per standard of care
- 5-year follow-up
- Multicentre
- Post hoc sensitivity analyses
- After the first year, antiplatelet therapy per standard of care
Primary result
As reported in the abstract
MACE
Hazard ratio (95% CI)P value
DAPT vs Aspirin monotherapy
0.65(0.43–0.99)
P = 0.04DAPT vs Ticagrelor monotherapy
0.66(0.44–1.00)
P = 0.05Original publication
Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. Published 11 June 2024. doi:10.
Summarised from the published abstract; every number is checked against it